Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. The company was founded in 2003 and is based in Chaozhou, China.
Часто задаваемые вопросы
В каком секторе работает Guangdong Hybribio Biotech Co Ltd (300639)?
Guangdong Hybribio Biotech Co Ltd относится к сектору Здравоохранение.
Какова текущая цена акций Guangdong Hybribio Biotech Co Ltd (300639)?
По последним данным, цена акций Guangdong Hybribio Biotech Co Ltd составляет 5,90 CN¥, предыдущее закрытие — 5,90 CN¥.
Выплачивает ли Guangdong Hybribio Biotech Co Ltd (300639) дивиденды?
Нет, Guangdong Hybribio Biotech Co Ltd не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Guangdong Hybribio Biotech Co Ltd (300639)?
У компании Guangdong Hybribio Biotech Co Ltd бета 0.416, что указывает на более низкую волатильность по сравнению с рынком в целом.